NYX 2925

Drug Profile

NYX 2925

Alternative Names: NYX-2925

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aptinyx
  • Class Small molecules
  • Mechanism of Action Neurotransmitter modulators; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibromyalgia; Neuropathic pain
  • Phase I Neurological disorders

Most Recent Events

  • 08 Mar 2018 Positive safety and pharmacokinetics data from a phase I trial in Healthy volunteers released by Aptinyx
  • 08 Mar 2018 Pharmacodynamics data from preclinical study in Neuropathic pain (chemotherapy-induced) released by Aptinyx
  • 14 Nov 2017 Pharmacodynamics data from preclinical studies in Neurological disorders presented at the 47th Annual Meeting of the Society for Neuroscience (SFN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top